v3.26.3
Revenue - Schedule of Product Sales (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue Recognition        
Total revenue $ 68,298 $ 70,445 $ 264,510 $ 976,340
Product sales        
Revenue Recognition        
Total revenue 25,693 13,442 86,747 645,844
Nuvaxovid sales        
Revenue Recognition        
Total revenue 0 (332) 9,558 605,599
Supply sales        
Revenue Recognition        
Total revenue $ 25,693 $ 13,774 $ 77,189 $ 40,245